Melatonin for Renal Protection in Patients Receiving Polymyxin B
Status:
Terminated
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study has the objective to evaluate the effect in renal function of 30mg of Melatonin
versus placebo in patients ≥18 years old treated with polymyxin B. The development of
nephrotoxicity will be evaluated by RIFLE(Risk, Injury, Failure, Loss, End stage renal
disease) score and KIM-1 urinary biomarker for the first 14 days of polymyxin B therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico Pontificia Universidade Católica do Rio Grande do Sul